---
figid: PMC6736652__cjcr-31-4-586-1
figtitle: Predictive biomarkers for bevacizumab efficacy in breast cancer
organisms:
- Homo sapiens
- Mus musculus
organisms_ner:
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
pmcid: PMC6736652
filename: cjcr-31-4-586-1.jpg
figlink: /pmc/articles/PMC6736652/figure/Figure1/
number: F1
caption: Overview of predictive biomarkers for bevacizumab efficacy in breast cancer.
  (A) Polymorphisms of several genes correlate with aberrant expression of critical
  proteins in angiogenic pathway; (B) Application of novel imaging methods allows
  in vivo tracing of bevacizumab perfusion in tumor tissues, and visualizing how they
  function on tumor; (C) Circulating angiogenic factors and endothelial cells promote
  neo-angiogenesis directly, and may serve as a noninvasive approach to assess angiogenic
  activities of tumors; (D) Combinations of multiple gene variables, tumor microvascular
  density or tumor characteristics profile the hallmark of breast cancer. SNP, single-nucleotide
  polymorphism; VEGF, vascular endothelial growth factor; IL-8, interleukin 8; AGTR1,
  angiotensin II receptor 1; RGD-USPIO, arginine-glycine-aspartic acid-labeled ultrasmall
  superparamagnetic iron oxide nanoparticles; VEGFR, vascular endothelial growth factor
  receptor; MMP, matrix metalloproteinases; CEC, circulating endothelial cell; CEP,
  circulating endothelial progenitor cell; Dll4, delta-like ligand 4; MVD, microvascular
  density.
papertitle: 'An update on biomarkers of potential benefit with bevacizumab for breast
  cancer treatment: Do we make progress?.'
reftext: Xu Liang, et al. Chin J Cancer Res. 2019 Aug;31(4):586-600.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.5322269
figid_alias: PMC6736652__F1
figtype: Figure
redirect_from: /figures/PMC6736652__F1
ndex: 1d477f19-deab-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6736652__cjcr-31-4-586-1.html
  '@type': Dataset
  description: Overview of predictive biomarkers for bevacizumab efficacy in breast
    cancer. (A) Polymorphisms of several genes correlate with aberrant expression
    of critical proteins in angiogenic pathway; (B) Application of novel imaging methods
    allows in vivo tracing of bevacizumab perfusion in tumor tissues, and visualizing
    how they function on tumor; (C) Circulating angiogenic factors and endothelial
    cells promote neo-angiogenesis directly, and may serve as a noninvasive approach
    to assess angiogenic activities of tumors; (D) Combinations of multiple gene variables,
    tumor microvascular density or tumor characteristics profile the hallmark of breast
    cancer. SNP, single-nucleotide polymorphism; VEGF, vascular endothelial growth
    factor; IL-8, interleukin 8; AGTR1, angiotensin II receptor 1; RGD-USPIO, arginine-glycine-aspartic
    acid-labeled ultrasmall superparamagnetic iron oxide nanoparticles; VEGFR, vascular
    endothelial growth factor receptor; MMP, matrix metalloproteinases; CEC, circulating
    endothelial cell; CEP, circulating endothelial progenitor cell; Dll4, delta-like
    ligand 4; MVD, microvascular density.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - VEGFA
  - CXCL8
  - AGTR1
  - CYREN
  - KDR
  - FLT1
  - FLT4
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - MMP9
  - MMP2
  - MVD
  - Vegfa
  - Cxcl15
  - Tshr
  - Agtr1a
  - Cyren
  - Kdr
  - Mmp9
  - Mmp2
  - Mvd
  - Flt4
  - Flt1
  - Pvf1
  - mri
  - Pvr
  - Pvf2
  - Pvf3
  - Zr
---
